PH12013502039B1 - Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) - Google Patents

Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Info

Publication number: PH12013502039B1
Authority: PH; Philippines
Prior art keywords: tfpi; monoclonal antibodies; tissue factor; pathway inhibitor; factor pathway
Prior art date: 2011-04-01

Application number

PH12013502039A

Other languages

English (en)

Other versions

PH12013502039A1 (en

Inventor

Zhuozhi Wang

John Murphy

Tobias Marquardt

Dieter Moosmayer

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2013-09-30

Publication date

2013-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013502039(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-30 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2013-12-16 Publication of PH12013502039A1 publication Critical patent/PH12013502039A1/en

2013-12-16 Publication of PH12013502039B1 publication Critical patent/PH12013502039B1/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PH12013502039A 2011-04-01 2013-09-30 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) PH12013502039B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161471101P	2011-04-01	2011-04-01
PCT/US2012/031538 WO2012135671A2 (en)	2011-04-01	2012-03-30	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (2)

Publication Number	Publication Date
PH12013502039A1 PH12013502039A1 (en)	2013-12-16
PH12013502039B1 true PH12013502039B1 (en)	2013-12-16

Family

ID=46932389

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PH12013502039A PH12013502039B1 (en)	2011-04-01	2013-09-30	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500439A PH12019500439A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500441A PH12019500441A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500440A PH12019500440A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
PH12019500439A PH12019500439A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500441A PH12019500441A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500440A PH12019500440A1 (en)	2011-04-01	2019-02-28	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Country Status (37)

Country	Link
US (5)	US20140294832A1 (2)
EP (1)	EP2694544B1 (2)
JP (4)	JP6170903B2 (2)
KR (2)	KR20190079698A (2)
CN (2)	CN107090046A (2)
AU (3)	AU2012236296A1 (2)
BR (1)	BR112013025376A2 (2)
CA (2)	CA3068997A1 (2)
CL (1)	CL2013002811A1 (2)
CO (1)	CO6890074A2 (2)
CR (1)	CR20130499A (2)
CU (1)	CU20130128A7 (2)
CY (1)	CY1121538T1 (2)
DK (1)	DK2694544T3 (2)
DO (1)	DOP2013000218A (2)
EA (2)	EA201991704A3 (2)
EC (1)	ECSP13012913A (2)
ES (1)	ES2722824T3 (2)
GT (1)	GT201300229A (2)
HK (1)	HK1243426A1 (2)
HR (1)	HRP20190467T1 (2)
HU (1)	HUE042706T2 (2)
IL (4)	IL228633B (2)
LT (1)	LT2694544T (2)
MX (1)	MX2013011218A (2)
MY (2)	MY190951A (2)
PE (1)	PE20141149A1 (2)
PH (4)	PH12013502039B1 (2)
PL (1)	PL2694544T3 (2)
PT (1)	PT2694544T (2)
RS (1)	RS58633B1 (2)
SG (2)	SG10201602606UA (2)
SI (1)	SI2694544T1 (2)
TR (1)	TR201905101T4 (2)
UA (1)	UA113623C2 (2)
WO (1)	WO2012135671A2 (2)
ZA (1)	ZA201308169B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2747721C (en)	2008-12-19	2021-07-20	Baxter International Inc.	Tfpi inhibitors and methods of use
CN102325795B (zh) †	2008-12-22	2015-03-25	诺沃—诺迪斯克有限公司	针对组织因子途径抑制剂的抗体
RS59830B1 (sr)	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
EP2547355B1 (en)	2010-03-19	2017-01-11	Baxalta GmbH	Tfpi inhibitors and methods of use
CN107090046A (zh) *	2011-04-01	2017-08-25	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
EP2827883B1 (en) *	2012-03-21	2019-05-08	Baxalta GmbH	Tfpi inhibitors and methods of use
SG11201406129QA (en) *	2012-03-30	2014-10-30	Bayer Healthcare Llc	Protease-regulated antibodies
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
ES2926773T3 (es) *	2013-03-15	2022-10-28	Novo Nordisk As	Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
US20160009818A1 (en)	2013-03-15	2016-01-14	Bayer Healthcare Llc	Anti-TFPI Antibody Variants with Differential Binding Across pH Range For Improved Pharmacokinetics
JP6584397B2 (ja) *	2013-07-19	2019-10-02	ノヴォノルディスクアー／エス	凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
CN106687482B (zh) *	2014-09-17	2022-01-25	诺和诺德股份有限公司	能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
EP4279128A3 (en)	2015-02-25	2024-02-28	Mogam Institute for Biomedical Research	Novel antibody binding to tfpi and composition comprising the same
IL302353A (en) *	2015-08-19	2023-06-01	Pfizer	TFPI inhibitory antibodies and their uses
CN112424593A (zh) *	2018-07-25	2021-02-26	索尼公司	凝血系统分析装置
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102325795B (zh) *	2008-12-22	2015-03-25	诺沃—诺迪斯克有限公司	针对组织因子途径抑制剂的抗体
RS59830B1 (sr) *	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
CN107090046A (zh) *	2011-04-01	2017-08-25	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
US8613919B1 (en) *	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations

2012
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown

Also Published As

Publication number	Publication date
IL274686A (en)	2020-06-30
BR112013025376A2 (pt)	2017-07-25
KR20140019428A (ko)	2014-02-14
GT201300229A (es)	2014-11-13
PH12013502039A1 (en)	2013-12-16
PL2694544T3 (pl)	2019-07-31
RS58633B1 (sr)	2019-05-31
MY165499A (en)	2018-03-27
EP2694544A2 (en)	2014-02-12
JP2018172411A (ja)	2018-11-08
IL228633B (en)	2018-03-29
AU2012236296A1 (en)	2013-10-24
CY1121538T1 (el)	2020-05-29
JP2017113019A (ja)	2017-06-29
PH12019500441A1 (en)	2020-10-12
NZ615969A (en)	2016-01-29
CR20130499A (es)	2013-10-24
EA201301107A1 (ru)	2014-11-28
WO2012135671A3 (en)	2012-12-13
WO2012135671A2 (en)	2012-10-04
US20190194353A1 (en)	2019-06-27
CA2831907A1 (en)	2012-10-04
JP6363747B2 (ja)	2018-07-25
HRP20190467T1 (hr)	2019-05-03
ZA201308169B (en)	2016-03-30
EP2694544B1 (en)	2019-01-23
IL283829A (en)	2021-07-29
MX2013011218A (es)	2013-10-17
CN107090046A (zh)	2017-08-25
KR101995302B1 (ko)	2019-07-02
IL257145A (en)	2018-03-29
JP6170903B2 (ja)	2017-07-26
SG193594A1 (en)	2013-10-30
EA201991704A2 (ru)	2020-03-31
KR20190079698A (ko)	2019-07-05
SG10201602606UA (en)	2016-04-28
CN103797030A (zh)	2014-05-14
CA2831907C (en)	2020-03-24
PE20141149A1 (es)	2014-08-28
DOP2013000218A (es)	2013-11-15
DK2694544T3 (en)	2019-04-15
HK1243426A1 (zh)	2018-07-13
JP2021019619A (ja)	2021-02-18
HUE042706T2 (hu)	2019-07-29
JP2014511685A (ja)	2014-05-19
ES2722824T3 (es)	2019-08-19
AU2019201814A1 (en)	2019-04-04
CA3068997A1 (en)	2012-10-04
IL228633A0 (en)	2013-12-31
EA034214B1 (ru)	2020-01-17
EP2694544A4 (en)	2015-03-25
EA201991704A3 (ru)	2020-06-30
US20220041752A1 (en)	2022-02-10
PH12019500439A1 (en)	2020-10-12
SI2694544T1 (sl)	2019-06-28
LT2694544T (lt)	2019-04-25
US20140294832A1 (en)	2014-10-02
UA113623C2 (uk)	2017-02-27
US20170107298A1 (en)	2017-04-20
CL2013002811A1 (es)	2014-02-28
PT2694544T (pt)	2019-04-02
CN103797030B (zh)	2017-05-31
US20180194857A1 (en)	2018-07-12
IL274686B (en)	2021-09-30
MY190951A (en)	2022-05-24
PH12019500440A1 (en)	2020-10-12
TR201905101T4 (tr)	2019-05-21
CU20130128A7 (es)	2014-03-26
ECSP13012913A (es)	2014-02-28
CO6890074A2 (es)	2014-03-10
AU2017203105A1 (en)	2017-06-01

Publication	Publication Date	Title
PH12019500440A1 (en)	2020-10-12	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500641A1 (en)	2019-07-29	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12017502286A1 (en)	2019-11-11	Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201390803A1 (ru)	2013-09-30	Ингибиторы бромодомена и их применение
TN2012000144A1 (en)	2013-09-19	Dll4-binding molecules
MX2020010535A (es)	2020-11-06	Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201490004A1 (ru)	2014-09-30	Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA201291034A1 (ru)	2013-04-30	АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
IN2014DN10386A (2)	2015-08-14
JOP20210044A1 (ar)	2017-06-16	الأجسام المضادة لـ cd38
MX357965B (es)	2018-08-01	Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
EA201400579A1 (ru)	2014-10-30	Антитела к il-36r
MX2013011922A (es)	2014-04-10	Compuestos de benceno substituido.
MX358224B (es)	2018-08-10	Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
UA107706C2 (uk)	2015-02-10	Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
EA201390506A1 (ru)	2013-09-30	Полипептиды, которые связывают компонент с5 комплемента человека
GB201109238D0 (en)	2011-07-13	Antibodies